New combo therapy aims to shrink tough tumors
Disease control
Ongoing
This study tests a new drug (ARRY-614) combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Apr 29, 2026 04:00 UTC